Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
نویسندگان
چکیده
منابع مشابه
Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
BACKGROUND The aim of this study was to assess the efficacy and safety of targeted radionuclide therapy with [90Y-DOTA0, Tyr3]-octreotide (90Y-DOTATOC) in patients with metastatic neuroendocrine tumors. PATIENTS AND METHODS One hundred and sixteen patients with metastatic neuroendocrine tumors were included. All patients were pre-therapeutically staged with morphological imaging procedures an...
متن کاملBiokinetic and Dosimetry of 90y-dotatoc Therapy for Neuroendocrine Tumours
Biokinetic model is a mathematical model which describes the behavior of the Y in human body during the treatment of neuroendocrine tumours. This paper presents calculation of absorbed doses in human organs in biokinetic model Y for DOTATOC therapy. For this purpose, the human body is represented by five compartments: blood, kidneys, urinary bladder, tumour and liver. The input file was develop...
متن کاملPeptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation.
BACKGROUND Breast cancer (BC) is the most frequent cancer in European women with nearly 30% of the patients eventually developing metastases. Neuroendocrine differentiation is a rare event, but overexpression of somatostatin receptors in BC has been reported in many studies. CASE REPORT A patient with liver metastases from BC was treated with peptide receptor radionuclide therapy (PRRT). Comp...
متن کاملthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
UNLABELLED Peptide receptor radionuclide therapy (PRRT) is a promising treatment for patients with neuroendocrine tumors, giving rise to improved survival. Dosimetric calculations in relation to PRRT have been concentrated to normal organ dosimetry in order to limit side effects. However, the relation between the absorbed dose to the tumor and treatment response has so far not been established....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 2013
ISSN: 0007-0920,1532-1827
DOI: 10.1038/bjc.2013.103